High-Volume Hemodiafiltration

Andrew Bland, MD, MBA, MS

Executive Summary

HVHDF combines diffusive and convective clearance to achieve 23–37% mortality reductions compared to conventional hemodialysis when convection volumes exceed 23 liters per session. Evidence base: five major RCTs (>4,000 patients), meta-analyses, and real-world data from >85,000 patients. FDA-cleared 5008X system available in the US since February 2024.

Clinical Evidence Foundation

Landmark Randomized Controlled Trials

Study	N (HD/HDF)	Mean Conv. Vol (L)	Primary Outcome	Key Finding
CONTRAST (2012)	356/358	19.8	All-cause mortality	No overall difference; >21.9 L: HR 0.62 (38% reduction)
Turkish OL-HDF (2013)	391/391	19.5	Mortality + CV events	>17.4 L: HR 0.71 (29% reduction)
ESHOL (2013)	450/456	23.9	All-cause mortality	30% reduction (HR 0.70, p=0.01); >25 L: 45% reduction
FRENCHIE	191/190	21.0	Intradialytic tolerance	Better tolerance; no mortality difference
CONVINCE (2023)	683/677	25.5	All-cause mortality	23% reduction (HR 0.77, p<0.001); cognitive preservation

IPD Meta-Analysis (Vernooij et al., 2024)

Combining all five RCTs, patients achieving convection volumes >23 L/session experienced:

37% reduction in all-cause mortality
42% reduction in cardiovascular mortality
49% reduction in infection-related mortality

Real-World Evidence

85,117 patients across 23 countries: 22% mortality reduction for HDF vs. high-flux HD, increasing to 30% at high-volume targets. Brazilian cohort (8,391 patients): 27% reduction, particularly pronounced in patients <65 years.

Mechanistic Understanding

Enhanced Solute Clearance

Beta-2 microglobulin clearance: 73 mL/min (nearly double high-flux HD)
Documented reductions in CRP, IL-6, and TNF-alpha
Reduced long-term dialysis-related amyloidosis

Hemodynamic Stability

50% reduction in symptomatic intradialytic hypotension
Gibbs-Donnan effect promotes sodium retention and plasma refilling
Cooling effect from substitution fluid infusion
Improved endothelial function and reduced arterial stiffness
Slower progression of vascular calcification

Infection Risk Reduction

31–49% reduction in infection-related mortality. Enhanced removal of immunosuppressive middle molecules (GIPs, free immunoglobulin light chains) restores immune competence. Improved vaccine response including higher antibody titers after influenza and SARS-CoV-2 vaccination.

Prescription Calculations

Core Formula

                Convection Volume (L) = [Qb (mL/min) × Time (min) × FF (%)] / 1000 + Net UF (L)
            

Example 1: Standard HVHDF Patient (75 kg, AVF)

                Qb = 370 mL/min | Time = 240 min | FF = 30% | Net UF = 2.5 L

                Blood volume = 370 × 240 / 1000 = 88.8 L

                Substitution = 88.8 × 0.30 = 26.6 L

                Convective vol = 26.6 + 2.5 = 29.1 L (exceeds 23 L target)

                Qd = 370 × 1.2 = 444 mL/min

                Effective FF = 29.1 / 88.8 = 32.8%

Example 2: Catheter-Limited Patient

                Qb = 300 mL/min | Time = 240 min | FF = 30% | Net UF = 2.0 L

                Blood volume = 300 × 240 / 1000 = 72.0 L

                Substitution = 72.0 × 0.30 = 21.6 L

                Convective vol = 21.6 + 2.0 = 23.6 L (borderline)

                Optimization A: Increase FF to 33% → 23.8 + 2.0 = 25.8 L

                Optimization B: Extend to 270 min → 81 × 0.30 = 24.3 + 2.0 = 26.3 L

Variable Selection Guide

Variable	Type	Range	Decision Points
Blood Flow (Qb)	Selected	330–400 mL/min	AVF/AVG: 350–400; CVC: 300–330
Treatment Time	Selected	210–270 min	Standard: 240; extend for CVC patients
Filtration Fraction	Selected	25–35%	Standard: 30%; max safe: 35%
Qd:Qb Ratio	Selected	1.0–1.5	Start at 1.2; adjust based on Kt/V
Convective Volume	Calculated	>23 L target	Substitution + net UF
Kt/V	Calculated	>1.4	Based on total (diffusive + convective) clearance

Progressive Implementation Protocol

Parameter	Week 1	Week 2	Week 3	Week 4	Week 5
Frequency	≥2	≥3	≥3	≥3	≥3
Time (min)	120–180	≤180	≤240	≤240	≥240
Qb (mL/min)	≤150	≤200	≤250	≤300	≥340
Post-dilution Qsub (L)	0	≤5	≤10	≤15	≥21
Dialysate Na (mEq/L)	140–143	140–142	140–141	139–140	138–140
spKt/V Target	—	—	—	≥1.4	≥1.4

Quality Assurance

                Monthly average target: >25 L convection volume

                Acceptable range: ±10% of target

                Investigation trigger: <23 L in >20% of sessions

Troubleshooting: Suboptimal Convection Volumes

                Current: Qb 320 × 240 × 0.28 / 1000 = 21.5 L (inadequate)

                Option A: Increase Qb to 350 → 23.5 L (+2.0 L)

                Option B: Extend to 270 min → 24.2 L (+2.7 L)

                Option C: Increase FF to 32% → 24.6 L (+3.1 L; monitor TMP)

Patient Selection

Optimal Candidates

Robust vascular access capable of high blood flows
Active transplant candidates (cardiovascular protection)
Patients with recurrent infections
Hemodynamic instability or heart failure
Dialysis-related amyloidosis or elevated beta-2 microglobulin

Infrastructure Requirements

Ultrapure water: ANSI/AAMI/ISO 23500-2019 (<0.1 CFU/mL, <0.03 EU/mL endotoxin)
Two-stage ultrafiltration achieving sterility assurance level of 6 magnitudes
Comprehensive staff training on optimization and troubleshooting

Medication Management

Dosing Adjustments Required

HVHDF's enhanced convective clearance increases removal of middle-molecular-weight drugs. Vancomycin: 1 g initially, then 500 mg at each of the next 3 sessions. Piperacillin/tazobactam and ceftazidime require post-dialysis dosing as for GFR 10–20 mL/min.

Small-molecule drugs cleared by diffusion: minimal changes
Highly protein-bound drugs: unaffected regardless of modality
MW 500–5,000 Da with low protein binding: may need TDM

United States Implementation Status

FDA clearance: 5008X system, February 2024
First US treatment: January 24, 2025 (Fresenius Kidney Care, Wellesley, MA) — 25.5 L substitution over 215 minutes
Global experience: >26,000 patients in FMC European/MENA clinics with mean convection volume of 27.4 L/session

Cost-Effectiveness

CONVINCE economic evaluation: ICER of €27,068–36,751/QALY over lifetime horizon, well below €50,000 threshold. Optimized HVHDF (Qd:Qb = 1.2 vs. 1.5) reduces dialysis fluid consumption by 26% (~26 L/session savings).

Clinical Pearl

The ability to reduce mortality by nearly 40% when delivered optimally places HVHDF among the most impactful interventions in nephrology. The challenge is no longer proving efficacy but ensuring equitable access and maintaining quality standards.

Key References

Vernooij RWM, et al. Individual patient data meta-analysis of HVHDF RCTs. 2024. PubMed Search
CONVINCE Study Group. HVHDF vs. high-flux HD: a multinational RCT. N Engl J Med. 2023;389(8):700-709. PubMed
Maduell F, et al. High-efficiency postdilution OL-HDF reduces mortality (ESHOL). J Am Soc Nephrol. 2013;24(3):487-497. PubMed
Grooteman MP, et al. OL-HDF and HD: CONTRAST trial. J Am Soc Nephrol. 2012;23(6):1087-1096. PubMed
Ok E, et al. Mortality and cardiovascular events in OL-HDF: Turkish study. Nephrol Dial Transplant. 2013;28(1):192-202. PubMed